NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Axis Technologies Group, Inc. (OTCPINK: AXTG) (the "Company" or "ATG"
https://finance.yahoo.com/news/axis-technolog...;tsrc=twtr
The Strength of Natural Diamonds in Today's Market As we enter a new year, the natural diamond market has shown a robust performance, providing encouraging signs of stability, strength, and growth. Jewelers have reported solid year-end results, showcasing steady or improved sales levels compared to previous periods. This positive trend reinforces the perception of natural...
Continue Reading
Overview of Bicara Therapeutics' Initial Public Offering Bicara Therapeutics Inc. (NASDAQ: BCAX), an innovative biopharmaceutical company currently in the clinical stage, has just taken an exciting step forward. They've announced the pricing for their initial public offering (IPO), which includes 17,500,000 shares of common stock, each priced at a competitive $18.00. This...
Continue Reading
Legal Update for Semtech Corporation Shareholders The Gross Law Firm has released an important notice specifically for shareholders of Semtech Corporation (NASDAQ: SMTC). This notice comes in light of a class action lawsuit that has been filed, and it outlines essential details regarding the lawsuit and actions that shareholders can take to safeguard their rights....
Continue Reading
Understanding the Investigation into Beyond Meat Beyond Meat, Inc. (NASDAQ: BYND), renowned for its innovative plant-based meat alternatives, is currently under scrutiny regarding potential violations of federal securities laws. This investigation, announced by a leading securities law firm, raises concerns for investors who may have suffered losses due to possible...
Continue Reading
Braving the Investor Circuit Immunic's ready to make some moves this July—this crew's diving headfirst into a trio of investor conferences. They're not just chitchatting; they’re taking one-on-one meetings, holding fireside chats. What’s the big draw? Their brainchild, vidofludimus calcium (IMU-838), which is knee-deep in phase 3 trials for relapsing multiple...
Continue Reading